286 related articles for article (PubMed ID: 9529005)
1. Thymosin fraction 5 inhibits the proliferation of the rat neuroendocrine MMQ pituitary adenoma and C6 glioma cell lines in vitro.
Spangelo BL; Farrimond DD; Thapa M; Bulathsinghala CM; Bowman KL; Sareh A; Hughes FM; Goldstein AL; Badamchian M
Endocrinology; 1998 Apr; 139(4):2155-62. PubMed ID: 9529005
[TBL] [Abstract][Full Text] [Related]
2. A novel thymosin peptide stimulates interleukin-6 release from rat C6 glioma cells in vitro.
Tijerina M; Gorospe WC; Bowman KL; Badamchian M; Goldstein AL; Spangelo BL
Neuroimmunomodulation; 1997; 4(3):163-70. PubMed ID: 9500150
[TBL] [Abstract][Full Text] [Related]
3. Thymosin fraction-5 possesses antiproliferative properties in HL-60 human promyelocytic leukemia cells: characterization of an active peptide.
Spangelo BL; Roach JD; Hadi F; Damavandy AA; Plieskatt J; Badamchian M
Ann N Y Acad Sci; 2007 Sep; 1112():305-16. PubMed ID: 17600287
[TBL] [Abstract][Full Text] [Related]
4. Thymosin fraction 5 stimulates prolactin and growth hormone release from anterior pituitary cells in vitro.
Spangelo BL; Judd AM; Ross PC; Login IS; Jarvis WD; Badamchian M; Goldstein AL; MacLeod RM
Endocrinology; 1987 Dec; 121(6):2035-43. PubMed ID: 2824178
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 beta and thymic peptide regulation of pituitary and glial cell cytokine expression and cellular proliferation.
Spangelo BL; Farrimond DD; Pompilius M; Bowman KL
Ann N Y Acad Sci; 2000; 917():597-607. PubMed ID: 11268388
[TBL] [Abstract][Full Text] [Related]
6. Presence of a peptide component of thymosin fraction-5 manifesting discrete cytostatic properties in HL-60 human promyelocytic leukemia cells.
Spangelo BL; Pompilius M; Farrimond DD; Stevens N; Nieva R; Shroff S; Badamchian M; Johnson CR; Jarvis WD
Int Immunopharmacol; 2005 Jul; 5(7-8):1317-29. PubMed ID: 15914336
[TBL] [Abstract][Full Text] [Related]
7. Thymosin fraction 5 (TF5) stimulates secretion of adrenocorticotropic hormone (ACTH) from cultured rat pituitaries.
McGillis JP; Hall NR; Goldstein AL
Life Sci; 1988; 42(22):2259-68. PubMed ID: 2453772
[TBL] [Abstract][Full Text] [Related]
8. Thymosin stimulates interleukin-6 production from rat spleen cells in vitro.
Attia WY; Badamchian M; Goldstein AL; Spangelo BL
Immunopharmacology; 1993; 26(2):171-9. PubMed ID: 8282541
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of epigallocatechin-gallate on brain tumor cell lines in vitro.
Yokoyama S; Hirano H; Wakimaru N; Sarker KP; Kuratsu J
Neuro Oncol; 2001 Jan; 3(1):22-8. PubMed ID: 11305413
[TBL] [Abstract][Full Text] [Related]
10. Thymosin enhances the production of IL-1 alpha by human peripheral blood monocytes.
Hu SK; Badamchian M; Mitcho YL; Goldstein AL
Lymphokine Res; 1989; 8(3):203-14. PubMed ID: 2789315
[TBL] [Abstract][Full Text] [Related]
11. Thymosin peptides stimulate corticotropin release by a calcium-dependent mechanism.
Goya RG; Castro MG; Hannah MJ; Sosa YE; Lowry PJ
Neuroendocrinology; 1993; 57(2):230-5. PubMed ID: 8389995
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of thymosin and other thymic factors on modulation of interleukin-2 production.
Zatz MM; Oliver J; Sztein MB; Skotnicki AB; Goldstein AL
J Biol Response Mod; 1985 Aug; 4(4):365-76. PubMed ID: 3875692
[TBL] [Abstract][Full Text] [Related]
13. Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells.
Hofland LJ; van Koetsveld PM; Wouters N; Waaijers M; Reubi JC; Lamberts SW
Endocrinology; 1992 Aug; 131(2):571-7. PubMed ID: 1322274
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo.
Pu P; Liu X; Liu A; Cui J; Zhang Y
J Neurosurg; 2000 Jan; 92(1):132-9. PubMed ID: 10616092
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application.
Hamilton HB; Hinton DR; Law RE; Gopalakrishna R; Su YZ; Chen ZH; Weiss MH; Couldwell WT
J Neurosurg; 1996 Aug; 85(2):329-34. PubMed ID: 8755764
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of a new human cultured cell line from a prolactin-secreting pituitary adenoma.
Kikuchi Y; Seki K; Momose E; Kizawa I; Oomori K; Shima K; Mukai K; Kato K
Cancer Res; 1985 Nov; 45(11 Pt 2):5722-7. PubMed ID: 4053045
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of thymosin. I. Thymosin fraction 5 increases lymphokine production by mature murine T cells responding in a mixed lymphocyte reaction.
Zatz MM; Goldstein AL
J Immunol; 1985 Feb; 134(2):1032-8. PubMed ID: 3155533
[TBL] [Abstract][Full Text] [Related]
18. Corticotropin-releasing (CRH) activity of thymic peptides on CRH-insensitive corticotropic tumor cells.
Goya RG; Castro MG; Hannah MJ; Sosa YE; Lowry PJ
Medicina (B Aires); 1993; 53(2):108-12. PubMed ID: 8295525
[TBL] [Abstract][Full Text] [Related]
19. A novel marine drug, SZ-685C, induces apoptosis of MMQ pituitary tumor cells by downregulating miR-200c.
Chen CH; Xiao WW; Jiang XB; Wang JW; Mao ZG; Lei N; Fan X; Song BB; Liao CX; Wang HJ; She ZG; Zhu YH
Curr Med Chem; 2013; 20(16):2145-54. PubMed ID: 23317100
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo.
Ikemoto S; Sugimura K; Wada S; Yasumoto R; Yamamoto K; Kishimoto T
Cancer Lett; 1999 Oct; 145(1-2):121-6. PubMed ID: 10530779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
